Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Brinks V"'
Publikováno v:
In Hormones and Behavior 2009 56(2):232-238
Publikováno v:
In Experimental Neurology 2009 216(2):375-382
Publikováno v:
In Progress in Brain Research 2007 167:257-261
Publikováno v:
Alimentary Pharmacology & Therapeutics. Nov2013, Vol. 38 Issue 10, p1188-1197. 10p. 1 Diagram, 2 Charts.
Publikováno v:
Analytical & Bioanalytical Chemistry. Jun2011, Vol. 400 Issue 1, p295-303. 9p. 2 Charts, 3 Graphs.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
van Meer, P.J.K., Kooijman, M., Brinks, V., Gispen-de Wied, C.C., Silva-Lima, B., Moors, E.H.M., Schellekens, H.
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved challenge in drug development. Non-human primates (NHPs) are often the only relevant animal model for the development of monoclonal antibodies (mAbs), but the immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::b14c6ca2d7e8e5f9abf78d5fc2a30648
https://dspace.library.uu.nl/handle/1874/313964
https://dspace.library.uu.nl/handle/1874/313964
Autor:
Brinks, V., Hawe, A., Basmeleh, A.H.H., Joachin-Rodriguez, L., Haselberg, R., Somsen, G.W., Jiskoot, W., Schellekens, H., Advanced drug delivery systems/drug targeting, Biomolecular Analysis, Innovation Studies, Farmaceutische Analyse, Pharmaceutics, Sub Biotechnological drugs, Sub Biomolecular analysis, Dep Farmaceutische wetenschappen
Publikováno v:
Brinks, V, Hawe, A, Basmeleh, A H H, Joachin-Rodriguez, L, Haselberg, R, Somsen, G W, Jiskoot, W & Schellekens, H 2011, ' Quality of Original and Biosimilar Epoetin Products ', Pharmaceutical research, vol. 28, no. 2, pp. 386-393 . https://doi.org/10.1007/s11095-010-0288-2
Pharmaceutical research, 28(2), 386-393. Springer New York
Pharmaceutical Research, 28(2), 386. Springer New York LLC
Pharmaceutical Research
Pharmaceutical research, 28(2), 386-393. Springer New York
Pharmaceutical Research, 28(2), 386. Springer New York LLC
Pharmaceutical Research
Purpose To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content, aggregation, isoform profile and potency. Methods Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b324fd00d54de7c994bd8c1429cb1fd5
https://research.vu.nl/en/publications/39260e3c-3373-4c09-9ec3-ce00c2bc94a7
https://research.vu.nl/en/publications/39260e3c-3373-4c09-9ec3-ce00c2bc94a7
Autor:
van Beers, M.M.C., Sauerborn, M.S., Gili, F., Hermeling, S., Brinks, V., Schellekens, H., Jiskoot, W.
To date, the therapeutic efficacy of recombinant human proteins is limited by their potential to break B cell tolerance in patients. The formation of neutralising antibodies (NABs) directed against recombinant human interferon beta (rhIFNβ) is assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::ccb71fac59d9141b8941cd8db80db712
https://dspace.library.uu.nl/handle/1874/42955
https://dspace.library.uu.nl/handle/1874/42955